SagE induces highly effective protective immunity against *Streptococcus iniae* mainly through an immunogenic domain in the extracellular region

Yun Sun¹,², Li Sun¹, Ming-qing Xing³, Chun-sheng Liu⁴ and Yong-hua Hu¹*

**Abstract**

**Background:** *Streptococcus iniae* is a Gram-positive bacterium and a severe pathogen of a wide range of farmed fish. *S. iniae* possesses a virulence-associated streptolysin S cluster composed of several components, one of which is SagE. SagE is a transmembrane protein with one major extracellular region named ECR. This study aimed to develop a SagE-based DNA candidate vaccine against streptococcosis and examine the immunoprotective mechanism of the vaccine.

**Results:** We constructed a DNA vaccine, pSagE, based on the *sagE* gene and examined its immunological property in a Japanese flounder (*Paralichthys olivaceus*) model. The results showed that at 7 days post-vaccination, expression of SagE at transcription and translation levels was detected in the tissues of the vaccinated fish. After challenge with *S. iniae* at one and two months post-vaccination, pSagE-vaccinated fish exhibited relative percent survival (RPS) of 95% and 88% respectively. Immunological analysis showed that (i) pSagE significantly upregulated the expression of a wide range of immune genes, (ii) pSagE induced the production of specific serum antibodies that bound whole-cell *S. iniae*, and (iii) treatment of *S. iniae* with pSagE-induced antibodies blocked bacterial invasion of host cells. To localize the immunoprotective domain of SagE, the ECR-expressing DNA vaccine pSagEECR was constructed. Immunization analysis showed that flounder vaccinated with pSagEECR exhibited a RPS of 68%, and that pSagEECR induced serum antibody production and immune gene expression in a manner similar to, though to lower magnitudes than, those induced by pSagE.

**Conclusions:** We in this study developed a DNA vaccine, pSagE, which induces highly protective immunity against *S. iniae*. The protective effect of pSagE is probably due to its ability to elicit systemic immune response, in particular that of the humoral branch, which leads to production of specific serum antibodies that impair bacterial infection. These results add insights to the immunoprotective mechanism of fish DNA vaccine.

**Keywords:** *Streptococcus iniae*, DNA vaccine, Immune response, Virulence

**Background**

*Streptococcus iniae* is one of the common bacterial pathogens associated with disease outbreaks in farmed fish [1,2]. It was first isolated from Amazon freshwater dolphin in the 1970s and has since become one of the leading fish pathogens [3]. *S. iniae* has a broad host range and is known to affect at least 27 species of fish, which include a large number of economically important species such as rainbow trout, tilapia, sea bass, channel catfish, barramundi, and Japanese flounder [4-9]. In China, streptococcal outbreaks have been reported in farmed freshwater and marine fish, notably flounder, turbot, tilapia, and red drum [10-14]. The frequency and outcome of disease outbreak are influenced by culture and environmental factors, and stress conditions, such as intensive aquaculture operations and high temperature, can lead to heavy stock mortality [15-17].

Experimental *S. iniae* vaccines in the forms of subunit vaccines [10,18], DNA vaccines [19], and attenuated live vaccines [20-23] have been reported by a number of research groups. However, none of these vaccines have been commercialized. To date, the only licensed vaccines
against *S. iniae* are bacterins consisting of inactivated whole-cell bacteria. In tilapia, it has been reported that killed bacterial cells combined with extracellular products produced effective protection [24]. Bacterins have been used to immunize farmed fish in Israel, Australia, Chile, and Spain [2,25,26]. However, the protectivity of inactivated vaccines proved to be limited [27,28].

In China, studies on *S. iniae* vaccines have begun only in recent years, and no licensed vaccines are available for aquaculture use. In Shandong Province of east China, *S. iniae* is recognized as a particularly severe pathogen for flounder and turbot, which are the principal economic fish species of the local area. In a previous study, we reported the construction of *S. iniae* DNA vaccines based on the *sagE*, *G*, and *I* genes of the streptolysin S cluster, which is known to be involved in the virulence of *S. iniae* [29-31]. We found that DNA vaccine plasmids expressing each of these genes induced effective protection. Since the streptolysin S locus is composed of nine genes, these observations led us to wonder whether other components of the streptolysin cluster also possess immunoprotective potential. To investigate this question, we in this study developed a DNA vaccine based on the *sagE* gene, another component of the streptolysin S cluster. We examined the immune response induced by SagE and its effect on bacterial infection. In addition, we also localized the main immunogenic region of SagE. Our results provide a useful vaccine candidate for the control of *S. iniae* and add insights to the protection mechanism of teleost DNA vaccines.

**Methods**

**Sequence analysis**

The amino acid sequence of SagE (GenBank accession no. AF465842.1) was analyzed using the BLAST program at the National Center for Biotechnology Information and the Expert Protein Analysis System. Subcellular localization was predicted with PSORTb version 3.0.2. Signal peptide search was performed with SignalP 3.0.

**Plasmid construction and preparation**

The primers used in this study are listed in Table 1. To construct pSagE, which expresses His-tagged SagE, *sagE* was amplified by PCR with primers SagEF1 and SagER1. The PCR product was inserted into pCN3 [32] at the SmaI site. pCN3 is a plasmid derived from pCI-neo (Promega, USA), a mammalian expression vector, and contains the human cytomegalovirus immediate-early enhancer/promoter, which promotes constitutive expression of cloned DNA inserts in mammalian cells, and the late SV40 polyadenylation signal, which increases the steady-state level of RNA. pSagECCR, which expresses His-tagged ECR, was constructed in the same fashion with the primer pair ECRF1/ECRR1. Endotoxin-free plasmid DNA was prepared using EndoFree plasmid Kit (Tiangen, Beijing, China). The purity of the purified DNA was analyzed spectrophotometrically by measuring absorbance at A_{260}/280 and A_{260}/230. The integrity of the plasmid DNA was assessed by agarose gel electrophoresis.

**Fish**

Japanese flounder (*Paralichthys olivaceus*) (average 11.2 g) were purchased from a local fish farm and acclimatized in the laboratory for two weeks before experimental manipulation. Fish were fed daily with commercial dry pellets and maintained at 20°C in aerated seawater. Before experiment, fish (5% of the stock) were randomly sampled for examination of bacterial recovery from blood, liver, kidney, and spleen as reported previously [33], and no bacteria were detected. ELISA analysis indicated that the randomly selected fish were negative of serum antibodies against *S. iniae*.

**Vaccination**

All vaccine plasmids were diluted in PBS to 150 μg/ml. For vaccination with pSagE, flounder were divided randomly into three groups (N = 70) and injected intramuscularly (i.m.) with 100 μl pSagE, pCN3, or PBS. At one and two months post-vaccination (pv), 25 fish were taken from each group and challenged via intraperitoneal (i.p.) injection with 100 μl *S. iniae* SF1 [10] that had been cultured in Luria-Bertani broth (LB) medium at 28°C to OD_{600} 0.8 and resuspended in PBS to 10^{7} CFU/ml. Vaccination with pSagECCR was performed in the same fashion. For all vaccination trials, mortality was monitored for 20 days, and dying fish were randomly selected for examination of bacterial recovery from liver, kidney, and spleen by plate count as described previously [33]. Relative percent survival (RPS) was calculated as described previously [34]. All vaccination trials were repeated once, and the mean mortality and RPS were given in the results.

### Table 1 Primers used in this study

| Primer   | Sequences (5' → 3')^a |
|----------|------------------------|
| CNF1     | CTTGGGGTTCTGATAGGACCTA |
| CNR1     | TGGCGGCTCTTGCTTTTTT |
| ECRF1    | CCCGGGACCGCCATGCGTTGCTTTTCAAA (SmaI) |
| ECRR1    | GTTCCGGGTAGATAGCAAAACCAT (SmaI) |
| ECRF2    | CCCGGGATGCGTTGCTTTCAAAA (SmaI) |
| SagEF1   | CCCGGGACCGCCATGCGTTGCTTTTC |
| SagER1   | GCCGGGACCGCCATGCGTTGCTTTTC |
| SagEF2   | ATGAAAAACCTGTCACAGGACTC |
| SagECR   | GCTAACGCATTCAACCACAAA |

^aUnderlined nucleotides are restriction sites of the enzymes indicated in the brackets at the ends.
Detection of plasmid DNA and vaccine gene expression
Muscle, kidney, liver, and spleen were taken from vaccinated fish at 7 days pv. For plasmid detection, DNA was extracted from the tissues with the TIANamp DNA Kit (Tiangen, Beijing, China) and used for PCR analysis with the primer pairs CNF1/SagER1 or CNF1/CNR1 (Table 1). To detect vaccine gene transcription, total RNA was extracted and used for reverse transcription-PCR (RT-PCR) as described previously [32] with α-tubulin as a reference [35]. Detection of vaccine protein by immunocolloidal gold electron microscopy was performed as reported previously [32].

Purification of recombinant protein
To obtain recombinant ECR (rECR), the plasmid pECR, which expresses ECR linked to a protein tag (Trx-tag) derived from the backbone plasmid pET32a (Novagen, San Diego, USA), the coding sequence of ECR was amplified by PCR with primers ECRF2 and ECRR1 (Table 1), and the PCR product was inserted into pET32a at the EcoRV site. Recombinant ECR (rECR), which was used for ELISA assay, was purified with nickel-nitrilotriacetic acid agarose (QIAGEN, Valencia, USA) according to manufacturer’s instructions. The purified protein was dialyzed for 24 h against phosphate-buffered saline (PBS) and concentrated using Amicon Ultra Centrifugal Filter Devices (Millipore, Billerica, MA, USA). The protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized after staining with Coomassie brilliant blue R-250 [see Additional file 1].

Enzyme-linked immunosorbent assay (ELISA)
Sera were collected from the vaccinated fish at one and two months pv and diluted 20 times in PBS. Serum antibodies against rECR was determined by ELISA, which was performed as reported previously [36]. Briefly, 96-well ELISA plates (Sangon, Shanghai, China) were coated with 0.05% (w/v) poly-L-lysine in coating buffer (0.159% Na₂CO₃, 0.293% NaHCO₃, pH 9.6) for 1 h, followed by washing the plates 3× with coating buffer. The plates were then coated with 100 μl/well purified recombinant protein dissolved in coating buffer (10 μg/ml) and incubated at 4°C for overnight. The plates were washed 3× with coating buffer and coated with 1% bovine serum albumin (BSA) at 22°C for 2 h, followed by washing 3× with PBST (0.1% Tween-20 in PBS). Diluted sera were added in triplicate to the wells of the plates. After incubation at 37°C for 2 h and washing with PBST, mouse anti-flounder IgM monoclonal antibody (Aquatic Diagnostic Ltd, Stirling, Scotland, UK) was added to the plates. The plates were incubated and washed as above. Horse-radish peroxidase-conjugated goat anti-mouse IgG (Bios, Beijing, China) was added to the plates. Color development was performed with the TMB Kit (Bios, Beijing, China). The plates were read at 450 nm with a Precision microplate reader (Molecular Devices, Canada).

Quantitative real time RT-PCR (qRT-PCR) to examine immune gene expression
Spleen was taken from the vaccinated fish at 24 h post-challenge. Total RNA extraction was performed as described above. qRT-PCR was carried out using the SYBR ExScript qRT-PCR Kit (Takara, Dalian, China) as described previously with α-tubulin as an internal reference [37].

Binding of vaccine-induced antibodies to bacterial cells
S. iniae SF1 was cultured as above and resuspended in PBS to 10⁹ CFU/ml. Fifty microliters of serum from pSagE- or pCN3-vaccinated fish was added to 0.5 ml S. iniae suspension, and the cells were incubated at 22 C for 1 h. The cells were collected by centrifugation, washed with PBS, and resuspended in 1 ml PBS. Mouse anti-flounder IgM monoclonal antibody (Aquatic Diagnostic, Scotland, UK) (1/100 dilution) was added to the cells. The cells were incubated, washed, and resuspended in PBS as above. Fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG (Bios, Beijing, China) (1/1000 dilution) was added to the cells. The cells were incubated, washed, and resuspended in PBS as above. Two hundred microliters of cell suspension was dropped onto a glass slide and observed with a fluorescence microscope (Nikon E800, Japan).

Effect of pSagE-induced antibodies on S. iniae infection
Flounder FG-9307 cell line was cultured at 22 C in 96-well cell culture plates with Eagle’s minimum essential medium (MEM) (GIBCO, Invitrogen, USA) as described previously [38]. For cellular infection, S. iniae SF1 in PBS (10⁸ CFU/ml) was mixed with serum from pSagE- or pCN3-vaccinated fish (1/10 dilution) at an equal volume. The mixture was incubated at room temperature for 0.5 h, and 10 μl of the mixture was added to each well of FG cells. The plates were incubated at 30 C for 4 h and washed three times with PBS. The cells were lysed with 1% Triton X-100, and 50 μl lyase was plated in triplicate on LB agar plates. After incubation at 30 C for 48 h, the colonies that appeared on the plates were counted.

Statistical analysis
All statistical analyses were performed with the SPSS 17.0 package (SPSS Inc., Chicago, IL, USA). Chi-square test with Yates’ correction was used for mortality analysis, and analysis of variance (ANOVA) was used for all other analyses. In all cases, the significance level was defined as P < 0.05.
Results

Sequence characterization of SagE
SagE is composed of 220 residues and predicted to be a cytoplasmic membrane protein. It contains a signal peptide (residues 1 to 25), two membrane-spanning regions (residues 39 to 61 and 74 to 96), and one major extracellular region (residues 97 to 143), which, for convenience, was named ECR [see Additional file 2].

Vaccine plasmid construction and expression of the vaccine gene in fish tissues following immunization
A SagE-expressing DNA vaccine, pSagE, was constructed. To examine the immunoprotective potential of pSagE, flounder were vaccinated with pSagE, the control vector pCN3, or PBS. At 7 days pv, PCR and RT-PCR were conducted to examine the presence of the vaccine plasmid and transcription of the vaccine gene respectively in muscle, kidney, liver, and spleen. The results showed that PCR detected pSagE and pCN3 in pSagE- and pCN3-vaccinated fish respectively but not in PBS-vaccinated fish, while RT-PCR detected sagE mRNA in pSagE-vaccinated fish only (Figure 1 and data not shown). To examine whether SagE protein was produced in the vaccinated fish, immunocollodial gold electron microscopy was carried out, which detected SagE protein in the muscle tissues of pSagE-vaccinated fish but not in pCN3- or PBS-vaccinated fish (Figure 2 and data not shown).

Protection induced by pSagE
The vaccinated fish were challenged at one and two months pv with S. iniae and monitored for mortality. The results showed that the accumulated mortalities of pSagE-, pCN3-, and PBS-vaccinated fish were 4%, 76%, and 82% respectively at one month pv, and 10%, 72%, and 80% respectively at two months pv. Hence, with PBS as a control, the RPS rates of pSagE-vaccinated fish were 95% and 88% at one and two months pv respectively.

Immune response induced by pSagE

Expression of immune genes
To investigate whether pSagE vaccination affected gene expression, qRT-PCR was conducted to examine the transcription level of immune genes in the spleen of pSagE- and pCN3-vaccinated fish at 24 h post-challenge. The immune genes examined were interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), interferon-...
(IFN)-γ, interferon-induced Mx protein, natural killer enhancing factor (NKEF), complement C3, immunoglobulin M (IgM) and D (IgD), major histocompatibility complex (MHC) class Iα and class IIα, CD40, and CD8α. The results showed that compared to control fish, fish vaccinated with pSagE exhibited significantly enhanced expression of all examined genes, with relatively high levels of induction (more than 5-fold) observed with TNF-α, IFN-γ, NKEF, C3, IgM, IgD, MHC Iα, MHC IIα, and CD40 (Figure 3).

Serum antibody production
ELISA showed that at one month pv, fish vaccinated with pSagE produced serum antibodies that recognized recombinant ECR (rECR) (Figure 4). A comparable level of antibody production was detected in pSagE-vaccinated fish at two months pv. No serum antibodies against rECR were detected in pCN3-vaccinated fish.

Interaction between serum antibodies and bacterial cells
Since SagE was predicted to be a membrane-localized protein, we examined whether it could be recognized in its natural state in S. iniae by pSagE-induced antibodies. For this purpose, live S. iniae was incubated with the serum from pSagE- or pCN3-vaccinated fish. The cell-bound antibodies were detected by FITC-labeled antibody. Microscopic examination showed that fluorescence was observed on the bacteria that had been treated with the serum from pSagE-vaccinated fish but not on the bacteria that had been treated with the serum from pCN3-vaccinated fish (Figure 5).

Effect of pSagE-induced antibodies on bacterial infection
To further examine whether pSagE-induced antibodies had any effect on S. iniae infection, the bacteria were treated with the serum from pSagE- or pCN3-vaccinated fish.
fish before being used for infection of flounder FG cells. The number of bacterial cells that succeeded in infection was subsequently determined. The results showed that compared to treatment with pCN3-induced serum, treatment with pSagE-induced serum significantly reduced (6.4-fold lower) the number of *S. iniae* recovered from FG cells [see Additional file 3].

**Localization of the immunoprotective region of SagE**

Since ECR is the major extracellular region of SagE, we examined its immunoprotective potential. For this purpose, flounder were vaccinated with pSagEECR, which expresses His-tagged ECR, pCN3, or PBS. At 7 days pv, RT-PCR detected the mRNA of ECR in the muscle, spleen, and kidney of pSagEECR-vaccinated fish, while immunocolloidal gold electron microscopy detected ECR protein in the muscle tissues of pSagEECR-vaccinated fish (data not shown). After challenging with *S. iniae* at one

**Figure 4** Serum antibody production in vaccinated fish. Sera were taken from flounder vaccinated with pSagE, pSagEECR, and PBS (control). Serum antibodies against ECR were determined by ELISA. Values are shown as means ± SE (N = 5). *P < 0.05; **P < 0.01.

**Figure 5** Interaction between vaccine-induced antibodies and bacterial cells. *Streptococcus iniae* was incubated with serum from pSagE-vaccinated fish (A and C) or with serum from control fish (B and D). Cell-bound antibodies were detected with FITC-labeled antibody. The cells were observed under a microscope with (A and B) or without (C and D) fluorescence.
month pv, the accumulated mortalities of pSagEECR-, pCN3-, and PBS-vaccinated fish were 23%, 62% and 72% respectively. Hence, the RPS rate of pSagEECR was 68% with PBS as a control.

ELISA showed that fish vaccinated with pSagEECR produced specific serum antibodies, but the antibody level was significantly lower than that in fish vaccinated with pSagE (Figure 4). qRT-PCR analysis showed that pSagEECR-vaccinated fish exhibited significantly enhanced expression of IL-1β, IL-6, TNF-α, IFN-γ, Mx, NKEF, complement C3, IgM, IgD, MHC Iα, MHC IIα, and CD40 (Figure 3); however, the induction folds of IL-6, IFN-γ, IgM, and IgD were lower than those in pSagE-vaccinated fish.

Discussion
It is known that in teleost, as in mammals, DNA vaccine plasmids administered via i.m. injection are transported to internal tissues, and the exogenous vaccine genes are expressed via the host’s expression system [39–41]. Likewise, in our study we found that following vaccination of flounder with pSagE, sagE mRNA and SagE protein were detected in multiple tissues at 7 days pv, suggesting that the DNA plasmid was taken up by host cells in local and distal tissues, where the sagE gene was successfully expressed. After challenge with S. iniae at one month pv, fish vaccinated with pSagE exhibited 95% survival, suggesting that an effective protective immunity was induced by pSagE in the vaccinated fish. At two months pv, pSagE-vaccinated fish displayed a RPS of 88%, which is comparable to that at one month pv, suggesting that the protective effect of pSagE lasted without significant decline for at least two months.

Compared to other types of vaccines, DNA vaccine possesses the advantage of being able to elicit systemic immune response of both the humoral and the cellular arms [42,43]. In the case of pSagE, qRT-PCR analysis showed that fish vaccinated with pSagE exhibited significantly enhanced expression of a range of genes, notably TNF-α, IFN-γ, NKEF, C3, IgM, IgD, MHC Iα, MHC IIα, and CD40, suggesting that in vivo expression of SagE stimulated innate and adaptive immunity. In line with the elevated expression of IgM, ELISA detected production of SagE specific serum antibodies in the vaccinated fish. Immunofluorescence microscopy showed that the antibodies from pSagE-vaccinated fish were able to bind live S. iniae, suggesting that SagE is naturally exposed on the cell surface of S. iniae.

Cellular infection analysis showed that when S. iniae was treated with pSagE-induced serum before incubation with FG cells, the number of bacteria recovered from the infected host cells was significantly reduced compared to that of the S. iniae pre-treated with the control serum. These results suggest that interaction between anti-SagE antibodies and the SagE on the surface of S. iniae inhibits S. iniae infection. Given the known involvement of streptolysin in S. iniae virulence [28,30], our results support the hypothesis that the immunoprotectivity of pSagE is probably due at least in part to its ability to induce production of specific serum antibodies, which, upon encountering S. iniae during subsequent infection, may inhibit the function of SagE and thus block S. iniae infection. Since ECR is the major extracellular region, we examined its potential protective effect. We found that the ECR-expressing DNA vaccine pSagEECR produced a RPS of 68%, suggesting that ECR contributes importantly to the protective effect of SagE. These results are consistent with those of ELISA analysis, which detected production of specific serum antibodies in pSagEECR-vaccinated fish, and qRT-PCR analysis, which showed that the expression patterns of immune genes induced by pSagEECR were largely similar to those induced by pSagE. However, both the antibody level and the magnitude of gene induction in pSagEECR-vaccinated fish were lower than those in pSagE-vaccinated fish, which may account for the lower protection of pSagEECR (compared to pSagE) and also suggest that in addition to ECR, there exit other immunogenic regions that are required to induce the full protective immunity observed with pSagE.

Conclusion
In conclusion, we in this study developed a DNA vaccine, pSagE, which induces highly protective immunity against S. iniae. The protective effect of pSagE is probably due to its ability to elicit systemic immune response, in particular that of the humoral branch, which leads to production of specific serum antibodies that impair bacterial infection. These results not only provide an effective candidate vaccine against streptococcosis but also add insights to the immunoprotective mechanism of teleost DNA vaccine.

Additional files

Additional file 1: SDS-PAGE analysis of purified recombinant ECR (rECR). Purified rECR (Lane 2) was resolved by SDS-PAGE and viewed after staining with Coomassie brilliant blue R-250. Lane 1, protein markers.

Additional file 2: Amino acid sequence of SagE. The putative signal peptide sequence is in italics, and the extracellular region ECR is underlined and in red.

Additional file 3: Effect of vaccine-induced antibodies on bacterial infection. FG cells were infected with Streptococcus iniae that had been treated with serum from fish vaccinated with pSagE or pCN3. The number of bacteria recovered from the infected FG cells was determined by plate count. Data are presented as means ± SE (N = 4). *P < 0.01.
Competing interests
The authors declare that they have no competing interests.

Authors' contributions
All authors participated in the study design. YS performed the experiments and acquired the data. LS designed the experiment. MX participated in the qRT-PCR analyses and the statistical analyses. CL participated in the animal experiment. YH made contributions to the conception of the study and wrote the manuscript. All authors revised the manuscript, and approved the final manuscript.

Acknowledgements
This work was supported by the grants of Shandong Scientific and Technological Project (2010035Y10511), the National Natural Science Foundation of China (3107230), and the Taishan Scholar Program of Shandong Province.

Author details
1Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
2Department of Clinical Laboratory, Qingdao Municipal Hospital, Qingdao 266000, China.
3Department of Clinical Laboratory, Qingdao Municipal Hospital, Qingdao 266000, China.
4Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
5Department of Clinical Laboratory, Qingdao Municipal Hospital, Qingdao 266000, China.

Received: 27 May 2013 Accepted: 3 November 2013

References
1. Law DE, Liu E, Fuller J, McGee A: Streptococcus iniae: an emerging pathogen in the aquaculture industry. In Emerging Infections J. Washington, DC: ASM Press; 1999:53–65.
2. Austin D, Austin B: Characteristics of the bacteria. In Bacterial Fish Pathogens: Disease of Farmed and Wild Fish. Berlin: Springer; 2008:181.
3. Agnew W, Barnes AC: Streptococcus iniae: an aquatic pathogen of global veterinary significance and a challenging candidate for reliable vaccination. Vet Microbiol 2007, 122:1–15.
4. Lahav D, Eynor M, Hurvitz A, Hettamir C, Lublin A, Eldar A: Streptococcus iniae type II infections in rainbow trout Oncorhyncus mykiss. Dis Aquat Org 2004, 62:177–180.
5. Shoemaker CA, Klesius PH, Evans JJ: Prevalence of Streptococcus iniae in cultured Japanese flounder (Paralichthys olivaceus) using selective isolation procedures. Dis Aquat Org 2004, 61:67–73.
6. Bortone ES, Ewers L: Infection of barramundi Lates calcarifer with Streptococcus iniae: effects of different routes of exposure. Dis Aquat Org 2002, 52:199–205.
7. Nguyen HT, Kana K, Yoshikoshi K: Ecological investigation of Streptococcus iniae in China. J Fish Dis 2008, 31:133–139.
8. Sun Y, Hu YH, Liu CS, Sun L: Construction and comparative study of monovalent and multivalent DNA vaccines against Streptococcus iniae. Fish Shellfish Immunol 2010, 29:598–603.
9. Eyngor M, Tekoah Y, Shapira R, Hurvitz A, Zlotkin A, Lublin A, Eldar A: Emergence of novel Streptococcus iniae exopolysaccharide-producing strains following vaccination with nonproducing strains. Appl Environ Microbiol 2008, 74:6892–6897.
10. Buchanan JT, Stannard JA, Lauth X, Ostland VE, Powell HC, Westernman ME, Nizet V: Streptococcus iniae phosphoglucomutase is a virulence factor and a target for a vaccine development. Infect Immun 2005, 73:6935–6944.
11. Locke JB, Aziz RK, Vicknair MR, Nizet V, Buchanan JT: Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live attenuated vaccine development. PLoS One 2008, 3:8284.
12. Buchanan JT, Stannard JA, Ostland VE, Nizet V, Buchanan JT: Evaluation of Streptococcus iniae killer strains and evaluation of its vaccines in hybrid striped bass through infection and bath immersion. Dis Aquat Organ 2010, 89:17–12.
13. Sun Y, Hu YH, Liu CS, Sun L: Construction and analysis of an experimental Streptococcus iniae DNA vaccine. Vaccine 2010, 28:3905–3912.
14. Buchanan JT, Stannard JA, Lauth X, Ostland VE, Powell HC, Westernman ME, Nizet V: Streptococcus iniae phosphoglucomutase is a virulence factor and a target for a vaccine development. Infect Immun 2005, 73:6935–6944.
15. Locke JB, Aziz RK, Vicknair MR, Nizet V, Buchanan JT: Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live attenuated vaccine development. PLoS One 2008, 3:8284.
16. Buchanan JT, Stannard JA, Ostland VE, Nizet V, Buchanan JT: Evaluation of Streptococcus iniae killer strains and evaluation of its vaccines in hybrid striped bass through infection and bath immersion. Dis Aquat Organ 2010, 89:17–12.
17. Yuasa K, Kitancharoen N, Kataoka Y, Al-Murbaty FA: Streptococcus iniae, the causative agent of mass mortality in rabbitfish Siganus canaliculatus in Bahrain. J Aquat Anim Health 1999, 11:87–93.
18. Zou L, Wang J, Huang B, Xie M, Li A, Mitsu: a hydrophobic membrane protein of Streptococcus iniae, is an effective subunit vaccine candidate. Vaccine 2011, 29:391–394.
19. Sun Y, Hu YH, Liu CS, Sun L: Construction and analysis of an experimental Streptococcus iniae DNA vaccine. Vaccine 2010, 28:3905–3912.
20. Buchanan JT, Stannard JA, Lauth X, Ostland VE, Powell HC, Westernman ME, Nizet V: Streptococcus iniae phosphoglucomutase is a virulence factor and a target for a vaccine development. Infect Immun 2005, 73:6935–6944.
21. Locke JB, Aziz RK, Vicknair MR, Nizet V, Buchanan JT: Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live attenuated vaccine development. PLoS One 2008, 3:8284.
22. Buchanan JT, Stannard JA, Ostland VE, Nizet V, Buchanan JT: Evaluation of Streptococcus iniae killer strains and evaluation of its vaccines in hybrid striped bass through infection and bath immersion. Dis Aquat Organ 2010, 89:17–12.
23. Prideon JW, Klesius PH: Development and efficacy of a novobiocin-resistant Streptococcus iniae as a novel vaccine in Nile tilapia (Oreochromis niloticus). Vaccine 2011, 29:5986–5993.
24. Klesius PH, Shoemaker CA, Evans JJ: Efficacy of single and combined Streptococcus iniae isolate vaccine administered by intraperitoneal and intramuscular routes in tilapia (Oreochromis niloticus). Aquaculture 2000, 188:237–246.
25. Hastein T, Gudding R, Evensten O: Bacterial vaccines for fish-an update of the current situation worldwide. Dev Biol (Basel) 2005, 121:55–74.
26. Sommerer J, Krosby B, Broering F, Frost P: Vaccines for fish in aquaculture. Expert Rev Vaccines 2005, 4:289–101.
27. Bachrach G, Zlotkin A, Hurvitz A, Evans DL, Eldar A: Recovery of Streptococcus iniae from diseased fish previously vaccinated with a Streptococcus vaccine. Appl Environ Microbiol 2001, 67:3756–3758.
28. Eyngor M, Tekoah Y, Shapira R, Hurvitz A, Zlotkin A, Lublin A, Eldar A: Emergence of novel Streptococcus iniae exopolysaccharide-producing strains following vaccination with nonproducing strains. Appl Environ Microbiol 2008, 74:6892–6897.
29. Sun Y, Hu YH, Liu CS, Sun L: Construction and comparative study of monovalent and multivalent DNA vaccines against Streptococcus iniae. Fish Shellfish Immunol 2012, 33:1305–1310.
30. Fuller JD, Camus AC, Duncan CI, Nizet V, Bast DJ, Thune RL, Low DE, Azavedo JCD: Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus iniae disease. Int J Food Microbiol 2002, 70:5730–5739.
31. Locke JB, Colvin KM, Varki N, Vicknair MR, Nizet V, Buchanan JT: Streptococcus iniae β-hemolysin streptolysin S is a virulence factor in fish infection. Dis Aquat Organ 2007, 76:1–7.
32. Jiao XD, Zhang M, Hu YH, Sun L: Construction and evaluation of DNA vaccines encoding Edwardsiella tarda antigens. Vaccine 2009, 27:5195–5202.
33. Zhang M, Sun K: Regulation of autoinducer 2 production and luxS expression in a pathogenic Edwardsiella tarda strain. Microbiology 2008, 154:2060–2069.
34. Wang HR, Hu YH, Zhang WW, Sun L: Construction of an attenuated Pseudomonas fluorescens strain and evaluation of its vaccines in hybrid striped bass through infection and bath immersion. Dis Aquat Organ 2007, 76:1–7.
35. Amend DF: Potency testing of fish vaccines. International Symposium on Fish Biologics: Serodiagnostics and Vaccines. Dev Biol Stand 1981, 49:447–454.
36. Jiao XD, Cheng S, Hu YH, Sun L: Comparative study of the effects of aluminum adjuvants and B Freund’s incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen. Vaccine 2010, 28:1832–1837.
37. Zheng WW, Sun L: Evaluation of housekeeping genes as references for quantitative real time RT-PCR analysis of gene expression in Japanese flounder (Paralichthys olivaceus). Fish Shellfish Immunol 2011, 30:638–645.
38. Tong SL, Li H, Mao HZ: The establishment and partial characterization of a continuous fish cell line FG-907 from the gill of flounder Paralichthys olivaceus. Aquaculture 1997, 56:327–333.
39. Boudinot P, Blanco M, de Kinkelin P, Benmansour A: Combined DNA immunization with the glycoprotein gene of viral hemorrhagic septicemia virus and infectious hematopoietic necrosis virus induces double-specific protective immunity and nonspecific response in rainbow trout. Virology 1998, 249:297–306.

40. Seternes T, Tonheim TC, Løvoll M, Bøgwald J, Dalmo RA: Specific endocytosis and degradation of naked DNA in the endocardial cells of cod (Gadus morhua L.). J Exp Biol 2007, 210:2091–2103.

41. Lorenzen N, Lorenzen E, Einer-Jensen K, LaPatra SE: DNA vaccines as a tool for analysing the protective immune response against rhabdoviruses in rainbow trout. Fish Shellfish Immunol 2002, 12:439–453.

42. Kurath G: Biotechnology and DNA vaccines for aquatic animals. Rev Sci Tech 2008, 27:75–196.

43. Tonheim TC, Bogwald J, Dalmo RA: What happens to the DNA vaccine in fish? A review of current knowledge. Fish Shellfish Immunol 2008, 25:1–18.

doi:10.1186/1751-0147-55-78

Cite this article as: Sun et al.: SagE induces highly effective protective immunity against Streptococcus iniae mainly through an immunogenic domain in the extracellular region. Acta Veterinaria Scandinavica 2013 55:78.